News - Part 2

Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody

Laureate to Manufacture ARIUS’ Product Candidate Trop-2 Signal Transduction Antibody Princeton, NJ, January 31, 2008: Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with ARIUS Research, Inc., a biotechnology company focused on discovering and developing the next wave of antibody therapeutics to treat cancer and other diseases, for its Trop-2 Signal Transduction Antibody Program. Laureate…

LAUREATE PHARMA ANNOUNCES AGREEMENT WITH TRUBION PHARMACEUTICALS

LAUREATE TO MANUFACTURE TRUBION’S TRU-016 PRODUCT CANDIDATE Princeton, NJ, January 30, 2007: Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced it has entered into an agreement to produce Trubion Pharmaceuticals, Inc.’s TRU-016, a novel protein for the treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Terms of the manufacturing agreement were not disclosed. Trubion’s TRU-016 program targets CD37, an antigen present on B…

Laureate Pharma to Produce Lpath’s Breakthrough Therapeutic Antibody for Phase I Clinical Trials

Laureate will manufacture recombinant Sphingomab™, a human therapeutic antibody for treatment of cancer and various ocular and cardiovascular conditions Princeton, New Jersey, and San Diego, California, August 22, 2006: Lpath, Inc. (OTC: LPTN), the first to generate therapeutic monoclonal antibodies against bioactive lipids, and Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that they have entered into an agreement to produce recombinant Sphingomab™. Sphingomab™ is…

LAUREATE PHARMA ANNOUNCES $9 MILLION EXPANSION OF MANUFACTURING FACILITY IN PRINCETON

PRINCETON, NJ – June 8, 2006 Laureate Pharma, a partner company of Safeguard Scientifics (NYSE: SFE), today announced plans to invest up to $9 million to expand its biopharmaceutical manufacturing facility in Princeton, NJ. The facility expansion will provide Laureate Pharma with a new pilot production plant with two separate production suites, and expanded purification production capacity to support additional cGMP production. The new pilot plant will include stainless steel…

LAUREATE PHARMA TO SPONSOR FREE WEBCAST ON DEVELOPMENT OF RADIOLABELED ANTIBODIES TO TREAT PROSTATE CANCER

PRINCETON, NJ – June 1, 2006 Laureate Pharma, a biopharmaceutical development and protein production company, is sponsoring a live webcast at 2PM EDT on June 8 on “Development Of A Third-Generation Antibody For Therapy Of Prostate Cancer.” The free webcast, presented by BioPharm International, will include presentations by experts from Cytogen Corporation, Laureate Pharma, and Memorial Sloan Kettering Cancer Center. The development of radiolabeled therapeutic antibodies is a sophisticated process…

LAUREATE PHARMA AND ICONIC THERAPEUTICS, INC. ANNOUNCE IMMUNOPROTEIN MANUFACTURING AGREEMENT

PRINCETON, NJ AND ATLANTA, GA – May 10, 2006 Laureate Pharma, Inc., a full service biopharmaceutical development and protein production company, today announced that it has entered into a biopharmaceutical manufacturing agreement with Iconic Therapeutics, Inc. for cGMP manufacture of hI-con1, a “bi-functional immunoprotein”. Laureate’s services include cGMP protein production, purification and aseptic filling of hI-con1 for Iconic Therapeutics. Terms of the agreement were not disclosed. “Iconic Therapeutics has a…

SEATTLE GENETICS AND LAUREATE PHARMA ANNOUNCE MANUFACTURING AGREEMENT

Bothell, WA and Princeton, NJ – April 25, 2006 Seattle Genetics, Inc. (Nasdaq: SGEN) and Laureate Pharma, Inc. announced today that they have entered into an agreement for manufacturing of Seattle Genetics SGN-33 and SGN-70 humanized monoclonal antibody product candidates. Under the terms of the agreement, Laureate Pharma will perform scale-up and cGMP manufacturing of clinical trial materials for both programs. “These manufacturing campaigns are an important part of our…

LAUREATE PHARMA AND BRADMER PHARMACEUTICALS ANNOUNCE AGREEMENT ON BRAIN CANCER TREATMENT PRODUCT

LAUREATE PHARMA AND BRADMER PHARMACEUTICALS ANNOUNCE THEIR DEVELOPMENT AND MANUFACTURING AGREEMENT ON A THERAPEUTIC MONOCLONAL ANTIBODY PRODUCT FOR TREATMENT OF BRAIN CANCER Princeton, NJ – March 16, 2006 – Laureate Pharma, Inc. announced today that it has entered into a biopharmaceutical development and manufacturing agreement with Bradmer Pharmaceuticals Inc. for process development and cGMP manufacture of the monoclonal antibody precursor of Neuradiab, Bradmer’s anticipated multi-center clinical candidate for treatment of…

LAUREATE PHARMA INC. ENTERS INTO AGREEMENT TO SELL ITS TOTOWA, NJ OPERATIONS TO DISCOVERY LABORATORIES FOR $16.0 MILLION

Laureate to Expand Its Bioprocessing Services at Princeton, NJ Facility Princeton, NJ – December 28, 2005 – Laureate Pharma, Inc., a provider of bioprocessing services to pharmaceutical and biopharmaceutical companies, announced today that it had agreed to sell its Totowa, NJ operations to Discovery Laboratories, Inc. (NASDAQ: DSCO) for $16.0 million in cash.  The transaction is expected to close shortly. Laureate Pharma is a wholly-owned subsidiary of Safeguard Scientifics, Inc….

Laureate Pharma and Enobia Pharma Announce Development and Manufacturing Agreement on Therapeutic Enzyme Product

PRINCETON, NJ – September 21, 2005 – Laureate Pharma, Inc. and Enobia Pharma, Inc. announced today that they have entered into a biopharmaceutical development and manufacturing agreement for process development and manufacture of cGMP batches of Enobia’s recombinant enzyme sPHEX Metallo Peptidase. The project is well underway and Laureate Pharma expects to supply Enobia with material for their Phase I clinical trials 3Q 2006. Terms of the agreement were not…